Gilead-Backed Aspen Neuroscience Shares Decline 2% After US IPO

Aspen Neuroscience Inc., a clinical-stage developer of cell therapies, fell 2% after raising about $140.6 million in a US initial public offering.

阅读完整 Veytics 简报

我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。